Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches

238Citations
Citations of this article
195Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Mitochondrial dysfunctions are central players in Alzheimer’s disease (AD). In addition, impairments in mitophagy, the process of selective mitochondrial degradation by autophagy leading to a gradual accumulation of defective mitochondria, have also been reported to occur in AD. We provide an updated overview of the recent discoveries and advancements on mitophagic molecular dysfunctions in AD-derived fluids and cells as well as in AD brains. We discuss studies using AD cellular and animal models that have unraveled the contribution of relevant AD-related proteins (Tau, Aβ, APP-derived fragments and APOE) in mitophagy failure. In accordance with the important role of impaired mitophagy in AD, we report on various therapeutic strategies aiming at stimulating mitophagy in AD and we summarize the benefits of these potential therapeutic strategies in human clinical trials.

Cite

CITATION STYLE

APA

Mary, A., Eysert, F., Checler, F., & Chami, M. (2023, January 1). Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. Molecular Psychiatry. Springer Nature. https://doi.org/10.1038/s41380-022-01631-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free